Skip to main content
Top
Published in: Intensive Care Medicine 2/2003

01-02-2003 | Brief Report

The use of the activated clotting time for monitoring heparin therapy in critically ill patients

Authors: Jan J. De Waele, Sebastiaan Van Cauwenberghe, Eric Hoste, Dominique Benoit, Francis Colardyn

Published in: Intensive Care Medicine | Issue 2/2003

Login to get access

Abstract

Objective

To determine the correlation between activated clotting time (ACT) and activated partial thromboplastin time (aPTT) in patients receiving intravenous unfractionated heparin therapy, and the accuracy of the ACT in predicting the level of anticoagulation.

Design

Paired aPTT and ACT measurements were obtained from a convenience sample of critically ill patients requiring intravenous unfractionated heparin. The aPTT was determined in the hospital laboratory and ACT measurements were performed with a portable device.

Setting

The intensive care unit of Ghent University Hospital, a tertiary care facility with 54 beds.

Patients and participants

Twenty-eight patients were studied prospectively; a total of 105 paired samples were obtained. The indication for heparin therapy was cerebral ischemia in 8, various cardiac conditions in 10, pulmonary embolism in 3, continuous hemofiltration in 3, and peripheral arterial thrombosis in 4.

Results

There was a significant correlation between aPTT and ACT. Analysis of variance showed a significant difference in ACT between different levels of anticoagulation, aPTT shorter than 60 s (group 1), aPTT 60–90 s (group 2), and aPTT longer than 90 s (group 3): 142±16.7 s in group 1 vs. 155±29.6 and 192±39.1 in groups 2 and 3.

Conclusions

The correlation between the aPTT and the ACT in this ICU setting is poor; ACT cannot differentiate between low and therapeutic levels of anticoagulation. The use of the ACT for monitoring low to moderate doses of heparin in ICU patients cannot be recommended.
Literature
1.
go back to reference Attia J, Ray JG, Cook DJ, Douketis J, Ginsberg JS, Geerts WH (2001) Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med 161:1268–1279PubMed Attia J, Ray JG, Cook DJ, Douketis J, Ginsberg JS, Geerts WH (2001) Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med 161:1268–1279PubMed
2.
go back to reference Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, de Feyter PJ, Specchia G, Ruzyllo W (2000) Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 21:1406–1432CrossRefPubMed Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, de Feyter PJ, Specchia G, Ruzyllo W (2000) Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 21:1406–1432CrossRefPubMed
4.
go back to reference Reeves JH, Cumming AR, Gallagher L, O'Brien JL, Santamaria JD (1999) A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med 27:2224–2228PubMed Reeves JH, Cumming AR, Gallagher L, O'Brien JL, Santamaria JD (1999) A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med 27:2224–2228PubMed
5.
go back to reference Hirsh J, Dalen JE, Deykin D, Poller L (1992) Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 102:337S-351SPubMed Hirsh J, Dalen JE, Deykin D, Poller L (1992) Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 102:337S-351SPubMed
6.
go back to reference Simko RJ, Tsung FF, Stanek EJ (1995) Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin. Ann Pharmacother 29:1015–1021PubMed Simko RJ, Tsung FF, Stanek EJ (1995) Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin. Ann Pharmacother 29:1015–1021PubMed
7.
go back to reference O'Neill AI, McAllister C, Corke CF, Parkin JD (1991) A comparison of five devices for the bedside monitoring of heparin therapy. Anaesth Intensive Care 19:592–596PubMed O'Neill AI, McAllister C, Corke CF, Parkin JD (1991) A comparison of five devices for the bedside monitoring of heparin therapy. Anaesth Intensive Care 19:592–596PubMed
8.
go back to reference Reiner JS, Coyne KS, Lundergan CF, Ross AM (1994) Bedside monitoring of heparin therapy: comparison of activated clotting time to activated partial thromboplastin time. Cathet Cardiovasc Diagn 32:49–52PubMed Reiner JS, Coyne KS, Lundergan CF, Ross AM (1994) Bedside monitoring of heparin therapy: comparison of activated clotting time to activated partial thromboplastin time. Cathet Cardiovasc Diagn 32:49–52PubMed
9.
go back to reference Melandri G, Branzi A, Traini AM, Semprini F, Cervi V, Magnani B (1993) On the value of the activated clotting time for monitoring heparin therapy in acute coronary syndromes. Am J Cardiol 71:469–471PubMed Melandri G, Branzi A, Traini AM, Semprini F, Cervi V, Magnani B (1993) On the value of the activated clotting time for monitoring heparin therapy in acute coronary syndromes. Am J Cardiol 71:469–471PubMed
10.
go back to reference Nath FC, Muller DW, Rosenschein U, Ellis SG, Topol EJ (1993) Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time. Can J Cardiol 9:797–801PubMed Nath FC, Muller DW, Rosenschein U, Ellis SG, Topol EJ (1993) Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time. Can J Cardiol 9:797–801PubMed
11.
go back to reference Uden DL, Payne NR, Kriesmer P, Cipolle RJ (1989) Procedural variables which affect activated clotting time test results during extracorporeal membrane oxygenation therapy. Crit Care Med 17:1048–1051PubMed Uden DL, Payne NR, Kriesmer P, Cipolle RJ (1989) Procedural variables which affect activated clotting time test results during extracorporeal membrane oxygenation therapy. Crit Care Med 17:1048–1051PubMed
12.
go back to reference Estes JW (1975) The laboratory control of heparin therapy. Curr Ther Res Clin Exp 18:58–65PubMed Estes JW (1975) The laboratory control of heparin therapy. Curr Ther Res Clin Exp 18:58–65PubMed
13.
go back to reference Banez EI, Triplett DA, Koepke J (1980) Laboratory monitoring of heparin therapy-the effect of different salts of heparin on the activated partial thromboplastin time. Am J Clin Pathol 74:569–574PubMed Banez EI, Triplett DA, Koepke J (1980) Laboratory monitoring of heparin therapy-the effect of different salts of heparin on the activated partial thromboplastin time. Am J Clin Pathol 74:569–574PubMed
14.
go back to reference Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, Anderson D, Johnson M (1994) A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 154:49–56PubMed Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, Anderson D, Johnson M (1994) A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 154:49–56PubMed
15.
go back to reference Murray DJ, Brosnahan WJ, Pennell B, Kapalanski D, Weiler JM, Olson J (1997) Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays. J Cardiothorac Vasc Anesth 11:24–28PubMed Murray DJ, Brosnahan WJ, Pennell B, Kapalanski D, Weiler JM, Olson J (1997) Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays. J Cardiothorac Vasc Anesth 11:24–28PubMed
16.
go back to reference Marci CD, Prager D (1993) A review of the clinical indications for the plasma heparin assay. Am J Clin Pathol 99:546–550PubMed Marci CD, Prager D (1993) A review of the clinical indications for the plasma heparin assay. Am J Clin Pathol 99:546–550PubMed
Metadata
Title
The use of the activated clotting time for monitoring heparin therapy in critically ill patients
Authors
Jan J. De Waele
Sebastiaan Van Cauwenberghe
Eric Hoste
Dominique Benoit
Francis Colardyn
Publication date
01-02-2003
Publisher
Springer-Verlag
Published in
Intensive Care Medicine / Issue 2/2003
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-002-1609-7

Other articles of this Issue 2/2003

Intensive Care Medicine 2/2003 Go to the issue